Hepatocellular carcinoma (HCC) is the 6th most malignant tumor and the 3rd leading cause of cancer death worldwide, with about 650,000 patients dying from HCC each year, of which 75% to 80% are from Asian countries, and the number of HCC patients in China accounts for 55% of the total number of patients worldwide. Because of the insidious onset of HCC, most patients are already in the middle and late stages when they are diagnosed, and less than 20% of patients can be surgically removed. Moreover, the high malignancy of HCC, the frequent combination of chronic hepatitis and cirrhosis, the ease of early dissemination and metastasis, and the high recurrence rate after surgery have seriously affected the prognosis and survival of HCC patients. In the past 30 years, interventional therapy represented by transcatheter hepatic artery chemoembolization (TACE) has become the main treatment for patients with unresectable HCC, which has not only improved the quality of life of many patients with intermediate to advanced stages, but also achieved efficacy comparable to that of surgical resection for early stage HCC. At present, there are many interventional minimally invasive techniques for liver cancer, and one to three interventional techniques can be used in the diagnosis and treatment of liver cancer to achieve good control of mid- to late-stage liver cancer. Comprehensive interventional minimally invasive techniques for liver cancer include: hepatic artery chemoembolization (TACE), percutaneous percutaneous tumor ablation (radiofrequency, microwave), argon-helium cryotherapy, radioactive particle implantation (125 iodine particles), etc.